论文部分内容阅读
目的:通过采用膈下逐瘀汤联合恩替卡韦片治疗瘀血阻络型慢乙肝来分析对患者血清肝纤维化指标影响。方法:选取本院2013年4月—2014年6月期间符合此次要求的100例瘀血阻络型慢乙肝患者纳入研究。按照随机数字表法分组为对照组和治疗组。对照组:采用恩替卡韦片0.5mg治疗;治疗组:在对照组治疗基础上加用膈下逐瘀汤治疗。观察患者治疗前、后血清纤维化指标及实验室指标、不良反应情况。结果:治疗后,治疗组HA、LN、PCIII、IVC分别为(82.96±32.15)ng/m L、(109.87±32.69)ng/m L、(97.01±11.97)ng/m L、(77.96±15.97)ng/m L与对照组(197.75±25.01)ng/m L、(127.85±31.05)ng/m L、(13169±56.97)ng/m L、(87.23±56.97)ng/m L比较(P<0.05)。治疗前各项实验室指标比较(P>0.05),治疗后实验室各项指标均得到明显改善,但治疗组优于对照组(P<0.05);治疗组不良反应率为4.00%(2/50)明显低于对照组12.00%(6/50)(P<0.05)。结论:采用膈下逐瘀汤联合恩替卡韦片治疗瘀血阻络型慢乙肝,其可改善患者血清肝纤维化指标和实验室指标,促进患者康复,且较为安全。
OBJECTIVE: To analyze the effect of serum hypoglycemic markers on liver fibrosis in patients with chronic obstructive jaundice by applying Gexia Zhuyu Decoction combined with entecavir tablets. Methods: A total of 100 patients with chronic obstruction of blood stasis syndrome were enrolled in this study from April 2013 to June 2014 in our hospital. In accordance with the random number table method for the control group and treatment group. Control group: the use of entecavir 0.5mg treatment; treatment group: in the control group based on the addition of treatment of sub-gxiaizhuyu decoction. Patients before and after treatment to observe serum fibrosis and laboratory indicators, adverse reactions. Results: After treatment, the levels of HA, LN, PCIII and IVC in the treatment group were (82.96 ± 32.15) ng / m L, (109.87 ± 32.69) ng / m L, (97.01 ± 11.97) ng / m L, (77.96 ± 15.97 (P <0.05). Compared with the control group (197.75 ± 25.01) ng / m L, (127.85 ± 31.05) ng / m L, (13169 ± 56.97) ng / m L and (87.23 ± 56.97) ng / <0.05). The indexes in laboratory before treatment were significantly improved (P <0.05), and the indexes in laboratory were improved obviously after treatment, but the treatment group was better than the control group (P <0.05). The adverse reaction rate in the treatment group was 4.00% (2 / 50) was significantly lower than the control group 12.00% (6/50) (P <0.05). Conclusion: The treatment of chronic obstructive jaundice by using Gexia Zhuyu Decoction combined with entecavir Tablets can improve the serum hepatic fibrosis indexes and laboratory indexes in patients, promote the recovery of patients and is safer.